Anti-cd40 antibodies and methods of use
AssigneeApexigen, Inc.
InventorsYongke ZHANG, Guo-Liang YU, Weimin ZHU
Life of this patent
Estimating the term…
Abstract
The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
Claims12
1-25. (canceled)
A method for treating or ameliorating the symptoms in a patient having a cancer, comprising administering to the patient the composition comprising a physiologically acceptable carrier and a therapeutically effective amount of an isolated antibody, or an antigen-binding fragment thereof, that binds to CD40, thereby treating or ameliorating the symptoms in the patient having the cancer,
- wherein the isolated antibody or antigen-binding fragment thereof comprises (i) a heavy chain variable region comprising the VHCDR1 region set forth in SEQ ID NO:3, the VHCDR2 region set forth in SEQ ID NO:4, and the VHCDR3 region set forth SEQ ID NO:5;
- and (ii) a light chain variable region comprising the VLCDR1 region set forth in SEQ ID NO:6, the VLCDR2 region set forth in SEQ ID NO:7, and the VLCDR3 region set forth in SEQ ID NO:
- 8;
- or a variant of said antibody, or an antigen-binding fragment thereof, comprising heavy and light chain variable regions identical to the heavy and light chain variable regions of (i) and (ii) except for up to 8 amino acid substitutions in said CDR regions.
A method for ameliorating symptoms in a patient having an autoimmune disease comprising administering to the patient the composition comprising a physiologically acceptable carrier and a therapeutically effective amount of an isolated antibody, or an antigen-binding fragment thereof, that binds to CD40, thereby ameliorating symptoms in the patient having the autoimmune disease,
- wherein the isolated antibody or antigen-binding fragment thereof comprises (i) a heavy chain variable region comprising the VHCDR1 region set forth in SEQ ID NO:3, the VHCDR2 region set forth in SEQ ID NO:4, and the VHCDR3 region set forth SEQ ID NO:5;
- and (ii) a light chain variable region comprising the VLCDR1 region set forth in SEQ ID NO:6, the VLCDR2 region set forth in SEQ ID NO:7, and the VLCDR3 region set forth in SEQ ID NO:
- 8;
- or a variant of said antibody, or an antigen-binding fragment thereof, comprising heavy and light chain variable regions identical to the heavy and light chain variable regions of (i) and (ii) except for up to 8 amino acid substitutions in said CDR regions.
A method for ameliorating symptoms in a patient having an inflammatory disease comprising administering to the patient the composition of claim comprising a physiologically acceptable carrier and a therapeutically effective amount of an isolated antibody, or an antigen-binding fragment thereof, that binds to CD40, thereby ameliorating symptoms in the patient having the inflammatory disease,
- wherein the isolated antibody or antigen-binding fragment thereof comprises (i) a heavy chain variable region comprising the VHCDR1 region set forth in SEQ ID NO:3, the VHCDR2 region set forth in SEQ ID NO:4, and the VHCDR3 region set forth SEQ ID NO:5;
- and (ii) a light chain variable region comprising the VLCDR1 region set forth in SEQ ID NO:6, the VLCDR2 region set forth in SEQ ID NO:7, and the VLCDR3 region set forth in SEQ ID NO:
- 8;
- or a variant of said antibody, or an antigen-binding fragment thereof, comprising heavy and light chain variable regions identical to the heavy and light chain variable regions of (i) and (ii) except for up to 8 amino acid substitutions in said CDR regions.
An isolated antibody, or an antigen-binding fragment thereof, that binds to CD40, comprising (i) a heavy chain variable region comprising the VHCDR1, VHCDR2, and VHCDR3 of any one of the VH regions shown in FIG. 16;
- and (ii) a light chain variable region comprising the VLCDR1, the VLCDR2, and the VLCDR3 region of the corresponding VL region of any one of the antibodies shown in FIG. 16;
- or a variant of said antibody, or an antigen-binding fragment thereof, comprising heavy and light chain variable regions identical to the heavy and light chain variable regions of (i) and (ii) except for up to 8 amino acid substitutions in said CDR regions.
Dependencies are inferred from the claim text.